GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
41.22
+0.36 (+0.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close40.86
Open41.15
Bid41.00 x 1300
Ask41.90 x 900
Day's Range40.95 - 41.28
52 Week Range31.43 - 48.25
Volume2,701,985
Avg. Volume3,364,082
Market Cap103.151B
Beta (5Y Monthly)0.44
PE Ratio (TTM)41.55
EPS (TTM)0.99
Earnings DateFeb 01, 2017 - Feb 06, 2017
Forward Dividend & Yield1.89 (4.58%)
Ex-Dividend DateMay 14, 2020
1y Target Est47.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Pedal to the Metal Leads to Record Rebound
    GuruFocus.com

    Pedal to the Metal Leads to Record Rebound

    Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades Continue reading...

  • GSK says within weeks of resubmitting HIV injection Cabenuva
    Reuters

    GSK says within weeks of resubmitting HIV injection Cabenuva

    GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday. ViiV executive Kimberly Smith told a media briefing that the company would stick to its previous guidance of refiling the request around mid-year and that this would happen "within weeks".

  • 3 Stocks With Low Forward Price-Earnings Ratios
    GuruFocus.com

    3 Stocks With Low Forward Price-Earnings Ratios

    Oracle tops the list Continue reading...

  • GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know
    Zacks

    GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know

    GlaxoSmithKline (GSK) closed at $40.55 in the latest trading session, marking a -1.39% move from the prior day.

  • Acquiring Biomarin Would Speed Sanofi Transition to New Therapies
    GuruFocus.com

    Acquiring Biomarin Would Speed Sanofi Transition to New Therapies

    French pharma giant seeks to exit heart and diabetes research and enter cancer and immune disease Continue reading...

  • The Promise and Perils of Owning Pfizer
    GuruFocus.com

    The Promise and Perils of Owning Pfizer

    The drugmaker offers a dividend yield of almost 4.5% Continue reading...

  • Sanofi Accelerates Coronavirus Vaccine Timeline, Says Approval Could Come In First Half Of 2021
    Benzinga

    Sanofi Accelerates Coronavirus Vaccine Timeline, Says Approval Could Come In First Half Of 2021

    Sanofi SA (NASDAQ: SNY), which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc (NYSE: GSK).Sanofi has also expanded its collaboration with mRNA vaccine company Translate Bio Inc (NASDAQ: TBIO).Sanofi Moves Up Vaccine Rollout Timeline: Sanofi said it expects to begin a Phase 1/2 study of the recombinant protein vaccine candidate it is co-developing with GlaxoSmithKline in September, and full approval is likely to be obtained at the earliest by the first half of 2021, the company said at its Virtual R&D Investor Day.GlaxoSmithKline is contributing its adjuvant AS03.In mid-April, when the companies announced the collaboration, they gave a timeline of the second half of 2021 for the probable commercial launch of the vaccine."Sanofi is advancing the only vaccine in the race that's off a proven platform that works at scale," Fierce Pharma reported, quoting Sanofi CEO Paul Hudson.Hudson expressed skepticism regarding the efficacy and the ability to scale manufacturing of the new breed of vaccines being developed by frontrunners working on the coronavirus. Translate Bio Pact: Sanofi is also strengthening its vaccine partnership with Translate Bio.The proposed expanded relationship is a collaboration and licensing agreement with the smaller biopharma to develop mRNA vaccines for infectious diseases, including COVID-19.Sanofi and Translate Bio are in the process of shortlisting a coronavirus mRNA vaccine candidate from animal studies and intend to start human trials in the fourth quarter of 2020.SNY Price Action: At last check, Sanofi shares were up 0.53% at $52.78.Related Links:The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout See more from Benzinga * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout * The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Sanofi eyes vaccine approval by early 2021
    Reuters Videos

    Sanofi eyes vaccine approval by early 2021

    Sanofi said Tuesday (June 23) it expects to get approval for a potential coronavirus vaccine by the first half of next year - faster than was previously thought. The French drugmaker is developing the medicine with Britain's GlaxoSmithKline. In April, they had said the vaccine would be available in the second half of 2021. Many drugmakers are racing to come up with a safe and effective vaccine that can be produced on a large scale. Moderna, AstraZeneca and Pfizer all moved to human trials as early as March. But Sanofi CEO Paul Hudson said their rivals were not assured of securing victory - and claimed moving at speed could lead to less effective results. He said the probability of success for his company is 'higher than anybody else'. Sanofi is currently working on two vaccine projects. Clinical trials of the drug developed with GSK are due to start in September. Sanofi said trials of a separate vaccine should begin around the end of 2020. The drugmaker said it had capacity to produce up to 1 billion doses a year of the vaccine it is working on with GSK.

  • Sanofi eyes approval of COVID-19 vaccine by first half of 2021
    Reuters

    Sanofi eyes approval of COVID-19 vaccine by first half of 2021

    French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. "We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.

  • The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern
    Zacks

    The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern

    The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern

  • Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine
    Zacks

    Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine

    Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.

  • GSK in quest to be best, not first, in race for COVID-19 vaccine
    Reuters

    GSK in quest to be best, not first, in race for COVID-19 vaccine

    There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline <GSK.L>. The company laid out plans in May to produce 1 billion doses of the efficacy boosters for COVID-19 shots next year, compared to the 700 million or so vaccine doses against a range of diseases it usually produces in a year.

  • GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
    Zacks

    GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

    GlaxoSmithKline (GSK) closed at $41.10 in the latest trading session, marking a +0.37% move from the prior day.

  • Top Analyst Reports for AbbVie, Oracle & GlaxoSmithKline
    Zacks

    Top Analyst Reports for AbbVie, Oracle & GlaxoSmithKline

    Top Analyst Reports for AbbVie, Oracle & GlaxoSmithKline

  • Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
    Zacks

    Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

    FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.

  • Moody's

    GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes

    Moody's Investors Service ("Moody's") has assigned an A2 rating to GSK Finance (No.3) plc's new exchangeable senior unsecured notes due 2023. - the proposed exchangeable notes do not provide loss absorption, in part because they could not lead to new equity creation.

  • Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers
    Zacks

    Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers

    FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.

  • MarketWatch

    GSK gets FDA approval for HIV drug for children

    Shares of GlaxoSmithKline were down 0.05% in premarket trading on Monday after the Food and Drug Administration late on Friday approved its HIV drug Tivicay as a treatment for infants and children. Tivicay is the company's second-best selling drug in its HIV portfolio. About 2,200 children in the U.S. had been diagnosed with HIV in 2016, according to statistics provided by the Centers for Disease Control and Prevention. GSK's stock has gained 14.9% since the start of the year. The S&P 500 is down 5.8% year-to-date. The FDA is granting the approval of Tivicay and Tivicay PD to ViiV Healthcare.

  • GuruFocus.com

    Sanofi Leads Second Tier of R&D Spenders

    GlaxoSmithKline's efficiency illustrates its ability to do more with less Continue reading...

  • GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
    Zacks

    GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

    GlaxoSmithKline (GSK) closed the most recent trading day at $40.42, moving +0.52% from the previous trading session.

  • Reuters

    U.S. FDA approves GSK unit's drug to treat infants and children with HIV

    The U.S. Food and Drug Administration has approved a drug to treat infants and children with HIV, with the drug having been developed by drugmaker GlaxoSmithKline's HIV drugs division ViiV Healthcare, the FDA and the GSK unit said. The FDA said on Friday it was granting Viiv the approval of Tivicay and Tivicay PD tablets "for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kgs in combination with other antiretroviral treatments". The drug is currently under review by the European Medicines Agency, ViiV, in which Pfizer and Shionogi have small stakes, said in a separate statement.

  • GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel
    PR Newswire

    GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel

    GlaxoSmithKline (LSE/NYSE: GSK) announced that Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1% (NSAID) arthritis pain reliever) recently became available over-the-counter (OTC) online and in stores nationwide, providing the over 30 million1 osteoarthritis patients across the country broader access to a leading pain relief option.

  • Top Pharmaceutical Stocks for Q3 2020
    Investopedia

    Top Pharmaceutical Stocks for Q3 2020

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

  • Reuters

    Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy

    Two drugs used to treat inflammatory diseases and cancer are being tested as potential therapies for patients with COVID-19, the Universities of Birmingham and Oxford announced on Wednesday. Severe cases of COVID-19 are believed to be triggered by an over-reaction of the immune system, known as a cytokine storm, and researchers are investigating whether drugs that suppress certain elements of the immune system can play a role in arresting a rapid escalation of symptoms. Izana Bioscience's Namilumab, a monoclonal antibody already in late-stage tests to treat rheumatoid arthritis and an inflammatory disease called ankylosing spondylitis, is the first of four candidates in the CATALYST trial.

  • GuruFocus.com

    Roche, Johnson & Johnson Top R&D Spenders in 2019

    Even with smaller budgets, emerging biotech companies are outpacing Big Pharma in drug discovery Continue reading...